Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)

NCT ID: NCT00480077

Last Updated: 2025-07-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

335 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The DOT-HF trial is an international, prospective, multi-center, randomized, controlled trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was designed with a Control Arm in order to adequately study the effect of early intervention triggered by the OptiVol® Alert and/or SentryCheck™ Monitor/PatientLook™ Indicator and evaluation using OptiVol® Fluid Status Monitoring with Cardiac Compass. OptiVol® Fluid Status Monitoring with Cardiac Compass features are available in the per Clinical Investigational Plan specified Medtronic products (CRT, CRT-D and ICD devices)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Intervention: in the access arm the patiens had programmmed the audible OptiVol Fliud status alert "on". Control patienst had programmed the audible alert "off"
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Access Arm

HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report

Group Type EXPERIMENTAL

Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )

Intervention Type DEVICE

OptiVol® Fluid status Monitoring with Cardiac Compass

Control arm

HF subjects managed with standard clinical assessment

Group Type ACTIVE_COMPARATOR

Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )

Intervention Type DEVICE

OptiVol® Fluid status Monitoring with Cardiac Compass

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )

OptiVol® Fluid status Monitoring with Cardiac Compass

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OptiVol® audible alert

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Subject is post heart transplant or actively listed on the transplant list and reasonable probability (as defined by investigator) of undergoing transplantation in the next year
* Subject received a coronary artery bypass graft or valve surgery in last 90 days
* Subject with a myocardial infarction (MI) in the last 40 days.
* Subject's life expectancy is less than one year in the opinion of the physician
* Subject has severe Chronic Obstructive Pulmonary Disease (COPD), as determined by physician and documented in medical records
* Subject is listed for valve replacement/valve repair
* Subject has severe, primary pulmonary hypertension as determined by physician and documented in medical records
* Subject with serum creatinine ≥ 2.5 mg/dL measured within 14 days prior to enrolment
* Subject on chronic renal dialysis
* Subject on continuous or uninterrupted (≥ 2 stable infusions per week) infusion (inotropic) therapy for HF
* Subject has complex and uncorrected Congenital Heart Disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Prof. D.J. van Veldhuisen, MD

Role: STUDY_CHAIR

Groningen University Hospital, The Netherlands

Prof. Dr. med. M. Borggrefe

Role: STUDY_CHAIR

Ruprecht-Karls-Universität Heidelberg, Germany

Prof. Dr. V. Conraads

Role: PRINCIPAL_INVESTIGATOR

Universitair Ziekenhuis Brussel

Prof. C.M. Yu

Role: PRINCIPAL_INVESTIGATOR

Prince of Wales Hospital, Shatin, Hong Kong

Dr. F. Braunschweig

Role: PRINCIPAL_INVESTIGATOR

Karolinska University Hospital

Prof. Dr. J. Kautzner

Role: PRINCIPAL_INVESTIGATOR

IKEM- Klinika Kardiologie, Czech Republic

Prof. Dr. G. Jondeau

Role: PRINCIPAL_INVESTIGATOR

Hôpital Bichat Claude Bernard, France

Prof. Dr. M.R. Cowie

Role: PRINCIPAL_INVESTIGATOR

National Heart & Lung Institute, United Kingdom

Dr. R. Muñoz-Aguilera

Role: PRINCIPAL_INVESTIGATOR

Hospital General Universitario Gregorio Marañon, Spain

Prof. I. Ford

Role: PRINCIPAL_INVESTIGATOR

Robertson Center for Biostatistics, Scotland

Dr. M Lunati

Role: PRINCIPAL_INVESTIGATOR

Azienda Ospedaliera Niguarda Ca' Granda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medtronic Bakken Research Center

Maastricht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, Kautzner J, Aguilera RM, Lunati M, Yu CM, Gerritse B, Borggrefe M; DOT-HF Investigators. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011 Oct 18;124(16):1719-26. doi: 10.1161/CIRCULATIONAHA.111.043042. Epub 2011 Sep 19.

Reference Type RESULT
PMID: 21931078 (View on PubMed)

Conraads VM, Spruit MA, Braunschweig F, Cowie MR, Tavazzi L, Borggrefe M, Hill MR, Jacobs S, Gerritse B, van Veldhuisen DJ. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure. Circ Heart Fail. 2014 Mar 1;7(2):279-87. doi: 10.1161/CIRCHEARTFAILURE.113.000883. Epub 2014 Feb 11.

Reference Type DERIVED
PMID: 24519908 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20061016-V2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CRT-P or CRT-D in Dilated Cardiomyopathy
NCT04139460 NOT_YET_RECRUITING NA